ArticleBone & joint research2025
The future of osteoarthritis treatment: exploring the potential of exosomes from adipose tissue-derived stem cells : a scoping review.
Article in Bone & joint research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aims: This review examines the therapeutic potential of adipose tissue-derived stem cell (ADSC) exosomes for osteoarthritis (OA), focusing on their anti-inflammatory and cartilage regeneration properties. Methods: A PubMed search (2012 to 2024) was conducted using keywords related to ADSCs, exosomes, and OA. Inclusion criteria focused on studies investigating ADSCs and ADSC-exosomes characteristics, animal OA models, and human OA patients. Exclusion criteria included case reports, case series, and conference abstracts. Results: ADSCs are an abundant stem cell source with low immunogenicity. ADSC-exosomes exhibit anti-inflammatory effects and promote cartilage regeneration via miRNA transport. Preclinical studies demonstrate inhibition of synovial thickening, cartilage destruction, and macrophage activity. Clinical trials suggest that intra-articular ADSCs are safe and effective, with higher doses improving pain relief and cartilage regeneration. Conclusion: ADSC-exosomes are a promising cell-free therapy for OA, with reduced immune rejection and tumorigenicity compared to ADSC transplantation. Standardizing exosome isolation and production remains a challenge. Further research is needed to confirm long-term safety and efficacy in humans.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.